Tipping the GVH/GVL balance by targeting HIF1α

Promoting GVL activity while eliminating GVHD is the utmost goal to treat hematological malignancies with allo-HCT. Bailey et al. demonstrate that targeting HIF1α can favor GVL activity while limiting GVHD after allo-HCT even in combination with immune checkpoint inhibition.(1)

Detalles Bibliográficos
Autores principales: Wu, Yongxia, Yu, Xue-Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694739/
https://www.ncbi.nlm.nih.gov/pubmed/37992679
http://dx.doi.org/10.1016/j.xcrm.2023.101295
Descripción
Sumario:Promoting GVL activity while eliminating GVHD is the utmost goal to treat hematological malignancies with allo-HCT. Bailey et al. demonstrate that targeting HIF1α can favor GVL activity while limiting GVHD after allo-HCT even in combination with immune checkpoint inhibition.(1)

Ejemplares similares